Advertisement

Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB

  • Tsutomu Shimada
  • Shunji TomatsuEmail author
  • Robert W. Mason
  • Eriko Yasuda
  • William G. Mackenzie
  • Jobayer Hossain
  • Yuniko Shibata
  • Adriana M. Montaño
  • Francyne Kubaski
  • Roberto Giugliani
  • Seiji Yamaguchi
  • Yasuyuki Suzuki
  • Kenji E. Orii
  • Toshiyuki Fukao
  • Tadao Orii
Research Report
Part of the JIMD Reports book series (JIMD, volume 21)

Abstract

Keratan sulfate (KS) is a storage material in mucopolysaccharidosis IV (MPS IV). However, no detailed analysis has been reported on subclasses of KS: mono-sulfated KS and di-sulfated KS. We established a novel method to distinguish and quantify mono- and di-sulfated KS using liquid chromatography–tandem mass spectrometry and measured both KS levels in various specimens.

Di-sulfated KS was dominant in shark cartilage and rat serum, while mono-sulfated KS was dominant in bovine cornea and human serum. Levels of both mono- and di-sulfated KS varied with age in the blood and urine from control subjects and patients with MPS II and IVA. The mean levels of both forms of KS in the plasma/serum from patients with MPS II, IVA, and IVB were elevated compared with that in age-matched controls. Di-sulfated KS provided more significant difference between MPS IVA and the age-matched controls than mono-sulfated KS. The ratio of di-sulfated KS to total KS in plasma/serum increased with age in control subjects and patients with MPS II but was age independent in MPS IVA patients. Consequently, this ratio can discriminate younger MPS IVA patients from controls. Levels of mono- and di-sulfated KS in urine of MPS IVA and IVB patients were all higher than age-matched controls for all ages studied.

In conclusion, the level of di-sulfated KS and its ratio to total KS can distinguish control subjects from patients with MPS II, IVA, and IVB, indicating that di-sulfated KS may be a novel biomarker for these disorders.

Keywords

Enzyme Replacement Therapy Skeletal Dysplasia Keratan Sulfate Sulfation Pattern Shark Cartilage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

Cre

Creatinine

DBS

Dried blood spot

ECM

Extracellular matrix

GAG

Glycosaminoglycans

Gal

d-galactose

GALNS

N-acetylgalactosamine-6-sulfate sulfatase

GlcNAc

N-acetyl-d-glucosamine

KS

Keratan sulfate

LC-MS/MS

High-performance liquid chromatography– tandem mass spectrometry

MPS

Mucopolysaccharidoses

NBS

Newborn screening

β-Gal

β-galactosidase

Notes

Acknowledgment

This work was supported by grants from the Austrian MPS Society and International Morquio Organization (Carol Ann Foundation). This work was also supported by Japanese MPS Family Society. R.W.M. and S.T. were supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of NIH under grant number P20GM103464. S.T. and A.M were supported by National Institutes of Health grant 1R01HD065767-02. The content of the article has not been influenced by the sponsors. F.K. was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico from Brazil (CNPq). Editorial assistance to the manuscript was provided by Michelle Stofa at Nemours/Alfred I. duPont Hospital for Children.

References

  1. Bhavanandan VP, Meyer K (1968) Studies on keratosulfates. Methylation, desulfation, and acid hydrolysis studies on old human rib cartilage keratosulfate. J Biol Chem 243:1052–1059PubMedGoogle Scholar
  2. Brown GM, Huckerby TN, Bayliss MT, Nieduszynski IA (1998) Human aggrecan keratan sulfate undergoes structural changes during adolescent development. J Biol Chem 273:26408–26414PubMedCrossRefGoogle Scholar
  3. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H (1998) Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 141:1277–1286PubMedCentralPubMedCrossRefGoogle Scholar
  4. Chinen Y, Higa T, Tomatsu S, Suzuki Y, Orii T, Hyakuna N (2014) Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep 1:31–41PubMedCentralPubMedCrossRefGoogle Scholar
  5. Dingle JT, Horsfield P, Fell HB, Barratt ME (1975) Breakdown of proteoglycan and collagen induced in pig articular cartilage in organ culture. Ann Rheum Dis 34:303–311PubMedCentralPubMedCrossRefGoogle Scholar
  6. Dũng VC, Tomatsu S, Montaño AM et al (2013) Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab 110:129–138PubMedCentralPubMedCrossRefGoogle Scholar
  7. Funderburgh JL (2000) Keratan sulfate: structure, biosynthesis, and function. Glycobiology 10:951–958PubMedCrossRefGoogle Scholar
  8. Funderburgh JL, Mitschler RR, Funderburgh ML, Roth MR, Chapes SK, Conrad GW (1997) Macrophage receptors for lumican. A corneal keratan sulfate proteoglycan. Invest Ophthalmol Vis Sci 38:1159–1167PubMedGoogle Scholar
  9. Graham RA, Li TC, Cooke ID, Aplin JD (1994) Keratan sulphate as a secretory product of human endometrium: cyclic expression in normal women. Hum Reprod 9:926–930PubMedGoogle Scholar
  10. Harmatz P, Mengel KE, Giugliani R et al (2013) The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab 109:54–61PubMedCrossRefGoogle Scholar
  11. Hendriksz CJ, Harmatz P, Beck M et al (2013) Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab 110:54–64PubMedCentralPubMedCrossRefGoogle Scholar
  12. Hintze JP, Tomatsu S, Fujii T et al (2011) Comparison of liquid chromatography-tandem mass spectrometry and sandwich ELISA for determination of keratan sulfate in plasma and urine. Biomark Insights 6:69–78PubMedCentralPubMedGoogle Scholar
  13. Imagama S, Sakamoto K, Tauchi R et al (2011) Keratan sulfate restricts neural plasticity after spinal cord injury. J Neurosci 31:17091–17102PubMedCrossRefGoogle Scholar
  14. Lauder RM, Huckerby TN, Nieduszynski IA (1997) The structure of the keratan sulphate chains attached to fibromodulin from human articular cartilage. Glycoconj J 14:651–660PubMedCrossRefGoogle Scholar
  15. Liles M, Palka BP, Harris A et al (2010) Differential relative sulfation of Keratan sulfate glycosaminoglycan in the chick cornea during embryonic development. Invest Ophthalmol Vis Sci 51:1365–1372PubMedCrossRefGoogle Scholar
  16. Martell LA, Cunico RL, Ohh J, Fulkerson W, Furneaux R, Foehr ED (2011) Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis 3:1855–1866PubMedCrossRefGoogle Scholar
  17. Möllmann C, Lampe CG, Müller-Forell W et al (2013) Development of a Scoring System to Evaluate the Severity of Craniocervical Spinal Cord Compression in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome). JIMD Rep 11:65–72PubMedCentralPubMedGoogle Scholar
  18. Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T (2007) International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis 30:165–174PubMedCrossRefGoogle Scholar
  19. Montaño AM, Tomatsu S, Brusius A, Smith M, Orii T (2008) Growth charts for patients affected with Morquio A disease. A J Med Genet A 146A:1286–1295CrossRefGoogle Scholar
  20. Nieduszynski IA, Huckerby TN, Dickenson JM et al (1990) There are two major types of skeletal keratan sulphates. Biochem J 271:243–245PubMedCentralPubMedGoogle Scholar
  21. Northover H, Cowie RA, Wraith JE (1996) Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis 19:357–365PubMedCrossRefGoogle Scholar
  22. Oguma T, Tomatsu S, Montano AM, Okazaki O (2007a) Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal Biochem 368:79–86PubMedCrossRefGoogle Scholar
  23. Oguma T, Tomatsu S, Okazaki O (2007b) Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography/turbo-ionspray ionization tandem mass spectrometry. Biomed Chromatogr 21:356–362PubMedCrossRefGoogle Scholar
  24. Ratcliffe A, Doherty M, Maini RN, Hardingham TE (1988) Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis 47:826–832PubMedCentralPubMedCrossRefGoogle Scholar
  25. Rowan DJ, Tomatsu S, Grubb JH, Montaño AM, Sly WS (2013) Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. J Inherit Metab Dis 36:235–246PubMedCentralPubMedCrossRefGoogle Scholar
  26. Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J (2011) Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr 100:456–460PubMedCrossRefGoogle Scholar
  27. Suzuki Y, Oshima A, Namba E (2001) β-Galactosidase deficiency (β-galactosidosis) GM1 gangliosidosis and Morquio B disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3775–3809Google Scholar
  28. Tai GH, Huckerby TN, Nieduszynski IA (1994) 600 MHz 1H NMR study of a fucose-containing heptasaccharide derived from a keratanase digestion of bovine articular cartilage keratan sulphate. Carbohydr Res 255:303–309PubMedCrossRefGoogle Scholar
  29. Tomatsu S, Okamura K, Maeda H et al (2005) Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 28:187–202PubMedCrossRefGoogle Scholar
  30. Tomatsu S, Montaño AM, Ohashi A et al (2008) Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet 17:815–824PubMedCrossRefGoogle Scholar
  31. Tomatsu S, Montaño AM, Oguma T et al (2010a) Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Mol Genet Metab 99:124–131PubMedCrossRefGoogle Scholar
  32. Tomatsu S, Montaño AM, Oguma T et al (2010b) Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. J Inherit Metab Dis 33:141–150PubMedCrossRefGoogle Scholar
  33. Tomatsu S, Montaño AM, Oguma T et al (2010c) Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J Inherit Metab Dis 33:S35–S42PubMedCrossRefGoogle Scholar
  34. Tomatsu S, Montaño AM, Oikawa H et al (2011) Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol 12:931–945PubMedCrossRefGoogle Scholar
  35. Tomatsu S, Mackenzie WG, Theroux MC et al (2012a) Current and emerging treatments and surgical interventions for Morquio A Syndrome: A review. Res Rep End Dis 2:65–77Google Scholar
  36. Tomatsu S, Montaño AM, Oikawa H et al (2012b) Impairment of Body Growth in Mucopolysaccharidoses, in: V.R. Preedy (Ed.), Handbook of Growth and growth monitoring in health and disease© Springer science + Businessmedia, LLC, 2091–2116.Google Scholar
  37. Tomatsu S, Fujii T, Fukushi M et al (2013a) Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab 110:42–53PubMedCentralPubMedCrossRefGoogle Scholar
  38. Tomatsu S, Alméciga-Díaz CJ, Barbosa H et al (2013b) Therapies of Mucopolysaccharidosis IVA (Morquio A Syndrome). Expert Opin Orphan Drugs 1:805–818PubMedCentralPubMedCrossRefGoogle Scholar
  39. Tomatsu S, Shimada T, Mason RW et al (2014) Assay for glycosaminoglycans by tandem mass spectrometry and its applications. J Anal Bioanal Tech S2:006. doi:10.4172/2155-9872.S2-006
  40. Weyers A, Yang B, Solakyildirim K et al (2013) Isolation of bovine corneal keratan sulfate and its growth factor and morphogen binding. FEBS J 280:2285–2293PubMedCentralPubMedCrossRefGoogle Scholar
  41. Yasuda E, Fushimi K, Suzuki Y et al (2013) Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder. Mol Genet Metab 109:301–311PubMedCrossRefGoogle Scholar
  42. Zhang Y, Kariya Y, Conrad AH, Tasheva ES, Conrad GW (2005) Analysis of keratan sulfate oligosaccharides by electrospray ionization tandem mass spectrometry. Anal Chem 77:902–910PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Tsutomu Shimada
    • 1
  • Shunji Tomatsu
    • 1
    • 7
    Email author
  • Robert W. Mason
    • 1
  • Eriko Yasuda
    • 1
  • William G. Mackenzie
    • 1
  • Jobayer Hossain
    • 1
  • Yuniko Shibata
    • 2
  • Adriana M. Montaño
    • 3
  • Francyne Kubaski
    • 1
  • Roberto Giugliani
    • 4
  • Seiji Yamaguchi
    • 5
  • Yasuyuki Suzuki
    • 6
  • Kenji E. Orii
    • 7
  • Toshiyuki Fukao
    • 7
  • Tadao Orii
    • 7
  1. 1.Nemours/Alfred I. duPont Hospital for ChildrenWilmingtonUSA
  2. 2.Central Research Laboratory, R&D DivisionSeikagaku Co.TokyoJapan
  3. 3.Department of PediatricsSaint Louis UniversitySt. LouisUSA
  4. 4.Medical Genetics Service/HCPA and Department of Genetics/UFRGSPorto AlegreBrazil
  5. 5.Department of PediatricsShimane UniversityIzumoJapan
  6. 6.Medical Education Development CenterGifu UniversityGifuJapan
  7. 7.Department of PediatricsGifu UniversityGifuJapan

Personalised recommendations